Details of the Drug Combinations

General Information of This Drug (ID: DM26CQR)

Drug Name

Larotrectinib DM26CQR

Synonyms

UNII-PF9462I9HX; PF9462I9HX; ARRY 470; Larotrectinib [USAN:INN]; GTPL8909; SCHEMBL2241012; NYNZQNWKBKUAII-KBXCAEBGSA-N; BDBM136597; ZINC118399834; AKOS027338709; example 14 [US8865698 B2]; CS-5722; HY-12866; AS-35231; J3.628.138C; US8865698, 14; ARRY470; ARRY-470

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Approved	[1]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

7 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Larotrectinib + JQ1	DCJT9I6	JQ1	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Larotrectinib + RTB101	DCSL9Q4	RTB101	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Larotrectinib + Daporinad	DCK0EF9	Daporinad	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Larotrectinib + Marizomib	DCT1TR6	Marizomib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Larotrectinib + PF-562271	DCHXM9M	PF-562271	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Larotrectinib + Rotenone	DC96CTX	Rotenone	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Larotrectinib + CB3304	DCQBFE0	CB3304	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 DrugCom(s)

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Larotrectinib + Gemcitabine	DCA9BXQ	Gemcitabine	Pancreatic Cancer	[3]
------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3	ClinicalTrials.gov (NCT04131192) Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer